Publicacións en colaboración con investigadores/as de Charité (37)

2024

  1. Consensus on criteria for acromegaly diagnosis and remission

    Pituitary, Vol. 27, Núm. 1, pp. 7-22

  2. Correction: consensus on criteria for acromegaly diagnosis and remission (Pituitary, (2024), 27, 1, (7-22), 10.1007/s11102-023-01360-1)

    Pituitary

2023

  1. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 936-955

  2. Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

    Pituitary, Vol. 26, Núm. 5, pp. 583-596

2022

  1. Development and validation of the food allergy severity score

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 5, pp. 1545-1558

  2. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  5. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  6. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

2021

  1. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 3, pp. 1020-1030.e10

  2. European guideline on igg4-related digestive disease — ueg and sgf evidence-based recommendations

    Russian Journal of Gastroenterology, Hepatology, Coloproctology, Vol. 31, Núm. 1, pp. 80-114

  3. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

  4. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 1041-1052

  5. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 629-647

2020

  1. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update

    Journal of Clinical Endocrinology and Metabolism, Vol. 105, Núm. 4, pp. E937-E946

  2. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

    European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392

  3. Multidisciplinary management of acromegaly: A consensus

    Reviews in Endocrine and Metabolic Disorders, Vol. 21, Núm. 4, pp. 667-678

  4. The tale in evolution: clarity, consistency and consultation, not contradiction and confusion

    Pituitary

2019

  1. A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement

    Pituitary, Vol. 22, Núm. 6, pp. 569-573